CervoMed says Phase 2a nfvPPA biomarker data will be presented at ISFTD 2026
CervoMed said initial 12-week biomarker results from its Phase 2a nfvPPA trial will be presented as a late-breaking oral session at ISFTD 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.